About Vor Biopharma
Vor Bio (Nasdaq: VOR) is a clinical-stage biotechnology company currently focused on advancing telitacicept, a novel dual-target BAFF/APRIL inhibitor fusion protein, through Phase 3 clinical development for autoimmune diseases including myasthenia gravis, systemic lupus erythematosus, and Sjögren's disease. Originally founded as a cell and genome engineering company targeting blood cancers, the company has pivoted to delivering therapies that restore balance to the immune system for patients with serious autoantibody-driven conditions worldwide.
Company details
Funding
Total raised
$152M
Last stage
Public
Investors
Founders
Siddhartha Mukherjee
Pulitzer Prize-winning author and Associate Professor of Medicine at Columbia University Medical Center; pioneered Vor's eHSC technology and lead product candidate VOR33.
Robert Ang
MBBS, MBA with over 20 years of experience in cell therapy, biotechnology, pharmaceuticals and medicine, including prior roles at Neon Therapeutics, Bavarian Nordic, Frazier Healthcare Ventures, and Boston Consulting Group.
LinkedInWhat happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.